Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Rating of “Buy” from Brokerages

by · The Markets Daily

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) has been assigned an average rating of “Buy” from the fourteen research firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $84.9091.

Several research analysts have recently issued reports on the company. HC Wainwright increased their price target on Mirum Pharmaceuticals from $80.00 to $81.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Citizens Jmp lifted their price objective on shares of Mirum Pharmaceuticals from $81.00 to $95.00 and gave the company a “market outperform” rating in a research note on Wednesday, November 5th. Raymond James Financial reiterated a “strong-buy” rating on shares of Mirum Pharmaceuticals in a research report on Thursday, August 7th. JMP Securities set a $95.00 target price on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 5th. Finally, TD Cowen raised shares of Mirum Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, September 25th.

Get Our Latest Stock Analysis on MIRM

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ:MIRM opened at $71.53 on Friday. The firm’s 50 day moving average is $71.62 and its two-hundred day moving average is $62.67. The firm has a market capitalization of $3.68 billion, a P/E ratio of -83.17 and a beta of 0.42. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. Mirum Pharmaceuticals has a 52 week low of $36.88 and a 52 week high of $78.54.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The business had revenue of $133.01 million during the quarter, compared to analyst estimates of $130.11 million. During the same period in the prior year, the company posted ($0.30) EPS. The business’s revenue for the quarter was up 47.1% compared to the same quarter last year. Analysts anticipate that Mirum Pharmaceuticals will post -1.43 earnings per share for the current year.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, Director Laura Brege sold 17,000 shares of the company’s stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $74.40, for a total value of $1,264,800.00. Following the completion of the sale, the director directly owned 15,703 shares in the company, valued at $1,168,303.20. This represents a 51.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Eric Bjerkholt sold 9,578 shares of Mirum Pharmaceuticals stock in a transaction on Friday, September 12th. The shares were sold at an average price of $76.01, for a total value of $728,023.78. Following the transaction, the chief financial officer owned 39,945 shares in the company, valued at approximately $3,036,219.45. This trade represents a 19.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 14.36% of the company’s stock.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the business. CWM LLC boosted its position in shares of Mirum Pharmaceuticals by 259.4% during the 1st quarter. CWM LLC now owns 593 shares of the company’s stock valued at $27,000 after purchasing an additional 428 shares in the last quarter. Victory Capital Management Inc. bought a new stake in shares of Mirum Pharmaceuticals in the 1st quarter worth approximately $213,000. Allianz Asset Management GmbH lifted its stake in Mirum Pharmaceuticals by 12.1% during the first quarter. Allianz Asset Management GmbH now owns 6,500 shares of the company’s stock valued at $293,000 after purchasing an additional 700 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Mirum Pharmaceuticals by 3.8% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,998 shares of the company’s stock worth $495,000 after buying an additional 398 shares in the last quarter. Finally, Federated Hermes Inc. grew its position in Mirum Pharmaceuticals by 9,440.4% in the first quarter. Federated Hermes Inc. now owns 347,366 shares of the company’s stock worth $15,649,000 after buying an additional 343,725 shares during the last quarter.

About Mirum Pharmaceuticals

(Get Free Report)

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

See Also